Patent ID: 8563036
Filing Date: 2013-10-22
Classification: A61K,A61P

Abstract:
1. A sustained release pharmaceutical composition comprising a core and, optionally, a coating, wherein the core comprises Brivaracetam as active ingredient and, as an excipient, at least one hydrophobic matrix agent or inert matrix agent in an amount that is 5% to 90% by weight of the composition, the matrix agent being a polymer which is a polymethacrylic acid derivative, or a non-polymer material which is a C8-C30 alcohol or lipid, or a non-polymer material having a melting point greater than 40° C., and wherein the composition is in solid form, and wherein the amount of Brivaracetam released in an in vitro buffered aqueous media (USP <711>Apparatus 2) is no more than 40% after 1 hour, 35%-80% after 4 hours, and no less than 80% after 16 hours.